Scott Koenig, M.D., Ph.D.

President and CEO
MacroGenics, Inc.

Dr. Scott Koenig joined the Alliance Board of Directors in 2014. He is a co-founder and President and CEO of MacroGenics (NASDAQ: MGNX), a biotechnology company developing immune-based medicines to treat patients with cancer, autoimmune disorders, and infectious diseases. Prior to joining MacroGenics in 2001, he served as Senior Vice President of Research at MedImmune where he participated in the selection and maturation of the product pipeline. From 1984 through 1990, he worked in the Laboratory of Immunoregulation at the National Institute of Allergy and Infectious Diseases (NIAID) where he investigated the immune response to retroviruses and studied the pathogenesis of AIDS.

Dr. Koenig is the Chairman of the Board of Directors at Applied Genetic Technologies Corporation (NASDAQ: AGTC), a biotech company developing genetic therapies for inherited diseases and Chairman of the Board of the Children’s Research Institute at Children’s National Medical Center. He co-chairs the Scientific Advisory Board of the Institute for Bioscience and Biotechnology Research at the University of Maryland. He also serves as a member of the MacroGenics Board of Directors, the Board of Directors of Children’s National Medical Center, the Biotechnology Industry Organization (BIO) Board of Directors, the Scientific Management Review Board of the NIH, and the Cornell University Council.

Dr. Koenig received his A.B. and Ph.D. from Cornell University and his M.D. from the University of Texas Health Science Center in Houston, where he was elected to Alpha Omega Alpha. He completed his residency in Internal Medicine at the Hospital of the University of Pennsylvania, and is Board certified in Internal Medicine and Allergy and Immunology. Scott and his wife, Robin, have been married for 35 years and have two children.